Sci Rep:前列腺肿瘤中,G84E变异对HOXB13基因和蛋白表达的影响研究

2018-01-06 AlexYang MedSci原创

HOXB13 G84E变异与前列腺癌风险相关,然而,该变异在PCa发展过程中的作用仍旧未知。最近,有研究人员在塔斯马尼亚调查了751个案例、450名亲属和355名对照来确定该变异对PCa风险的贡献机制,并且调查了HOXB13基因和蛋白在来自9个G843E杂合子变异样本和13个野生型携带者肿瘤中的表达情况。研究发现,定量PCR分析和免疫组化分析表明,HOXB13基因和蛋白在变异体和野生型携带者中的表

HOXB13 G84E变异与前列腺癌风险相关,然而,该变异在PCa发展过程中的作用仍旧未知。最近,有研究人员在塔斯马尼亚调查了751个案例、450名亲属和355名对照来确定该变异对PCa风险的贡献机制,并且调查了HOXB13基因和蛋白在来自9个G843E杂合子变异样本和13个野生型携带者肿瘤中的表达情况。

研究发现,定量PCR分析和免疫组化分析表明,HOXB13基因和蛋白在变异体和野生型携带者中的表达没有显著差异。等位基因特异性转录阐释了7个G84E携带者中的2个同时转录了变异的和野生型的等位基因,然而,其余5个案例只转录了野生型等位基因。另外,变异基因CpG位点周围甲基化程度要比野生型等位基因位点周围的更低,然而,野生型该区域的总的甲基化程度则非常低。明显的是,在该2个变异携带者中,肿瘤的侵入特性更低,并且这2个变异等位基因与其余5个相比较还可以转录变异等位基因。最后,研究人员指出,他们的研究表明了HOXB13基因的表达在G84E变异携带者和非携带者中没有差异。有趣的是,G84E变异等位基因在携带者中很少转录,表明了HOXB13基因的表达也许在大多数携带者中需要有野生型等位基因的驱使。

原始出处:

Liesel M. FitzGerald, Kelsie Raspin, James R. Marthick et al. Impact of the G84E variant on HOXB13gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours. Sci Rep. 19 Dec 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771466, encodeId=37f21e7146649, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Wed Aug 22 23:35:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342455, encodeId=dba013424559f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Jan 08 05:35:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532654, encodeId=fd91153265419, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Mon Jan 08 05:35:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276029, encodeId=d8942e602951, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 15:17:09 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771466, encodeId=37f21e7146649, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Wed Aug 22 23:35:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342455, encodeId=dba013424559f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Jan 08 05:35:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532654, encodeId=fd91153265419, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Mon Jan 08 05:35:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276029, encodeId=d8942e602951, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 15:17:09 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771466, encodeId=37f21e7146649, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Wed Aug 22 23:35:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342455, encodeId=dba013424559f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Jan 08 05:35:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532654, encodeId=fd91153265419, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Mon Jan 08 05:35:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276029, encodeId=d8942e602951, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 15:17:09 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-01-08 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771466, encodeId=37f21e7146649, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Wed Aug 22 23:35:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342455, encodeId=dba013424559f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Jan 08 05:35:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532654, encodeId=fd91153265419, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Mon Jan 08 05:35:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276029, encodeId=d8942e602951, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 15:17:09 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-01-06 1e0f8808m18(暂无匿称)

    好文章.学习了.

    0